References
- Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-65. https://doi.org/10.1161/01.CIR.0000102381.57477.50
- McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, et al. Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 2005;115:1479-91. https://doi.org/10.1172/JCI23203
- Dorfmüller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-63. https://doi.org/10.1183/09031936.03.00038903
- Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S- 24S. https://doi.org/10.1016/j.jacc.2004.02.029
- Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005;19:1178-80.
- Jankov RP, Kantores C, Belcastro R, Yi M, Tanswell AK. Endothelin-1 inhibits apoptosis of pulmonary arterial smooth muscle in the neonatal rat. Pediatr Res 2006;60:245-51. https://doi.org/10.1203/01.pdr.0000233056.37254.0b
- Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40. https://doi.org/10.1161/01.CIR.0000077913.60364.D2
- Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 2007;9 Suppl 2:S8. https://doi.org/10.1186/ar2192
- Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993;73:887-97. https://doi.org/10.1161/01.RES.73.5.887
- Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000;6:698-702. https://doi.org/10.1038/76282
- Ono S, Voelkel NF. PAF antagonists inhibit monocrotaline-induced lung injury and pulmonary hypertension. J Appl Physiol 1991;71: 2483-92. https://doi.org/10.1152/jappl.1991.71.6.2483
- Prié S, Leung TK, Cernacek P, Ryan JW, Dupuis J. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline-treated rats. J Pharmacol Exp Ther 1997;282:1312-8.
- Sakuma F, Miyata M, Kasukawa R. Suppressive effect of prostaglandin E1 on pulmonary hypertension induced by monocrotaline in rats. Lung 1999;177:77-88. https://doi.org/10.1007/PL00007632
- Lim KA, Shim JY, Cho SH, Kim KC, Han JJ, Hong YM. Effect of endothelin receptor blockade on monocrotaline-induced pulmonary hypertension in rats. Korean J Pediatr 2009;52:689-95. https://doi.org/10.3345/kjp.2009.52.6.689
- Lim KA, Kim KC, Cho MS, Lee BE, Kim HS, Hong YM. Gene expression of endothelin-1 and endothelin receptor a on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J 2010;40:459-64. https://doi.org/10.4070/kcj.2010.40.9.459
- Koo HS, Kim KC, Hong YM. Gene expressions of nitric oxide synthase and matrix metalloproteinase-2 in monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. Korean Circ J 2011;41:83-90. https://doi.org/10.4070/kcj.2011.41.2.83
- Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:34-8. https://doi.org/10.1164/rccm.200303-346OC
- Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, et al. Chronic sildenafil treatment inhibits monocrotaline- induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45. https://doi.org/10.1164/rccm.200302-282OC
- Booth AD, Jayne DR, Kharbanda RK, McEniery CM, Mackenzie IS, Brown J, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004;109:1718-23. https://doi.org/10.1161/01.CIR.0000124720.18538.DD
- Xiong W, MacTaggart J, Knispel R, Worth J, Persidsky Y, Baxter BT. Blocking TNF-alpha attenuates aneurysm formation in a murine model. J Immunol 2009;183:2741-6. https://doi.org/10.4049/jimmunol.0803164
- Bradham WS, Bozkurt B, Gunasinghe H, Mann D, Spinale FG. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res 2002;53:822-30. https://doi.org/10.1016/S0008-6363(01)00503-X
- Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 2008;75:346-9. https://doi.org/10.1159/000090248
- Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997; 24:663-5.
- ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002;50:206-11. https://doi.org/10.1136/gut.50.2.206
- Grundmann S, Hoefer I, Ulusans S, van Royen N, Schirmer SH, Ozaki CK, et al. Anti-tumor necrosis factor-{alpha} therapies attenuate adaptive arteriogenesis in the rabbit. Am J Physiol Heart Circ Physiol 2005;289:H1497-505. https://doi.org/10.1152/ajpheart.00959.2004
- Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 2000;14:2123-33. https://doi.org/10.1101/gad.815400
- Roten L, Nemoto S, Simsic J, Coker ML, Rao V, Baicu S, et al. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP-1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 2000;32:109-20. https://doi.org/10.1006/jmcc.1999.1052
- Kulik TJ. Pathophysiology of acute pulmonary vasoconstriction. Pediatr Crit Care Med 2010;11(2 Suppl):S10-4. https://doi.org/10.1097/PCC.0b013e3181c766c6
- Jankov RP, Luo X, Belcastro R, Copland I, Frndova H, Lye SJ, et al. Gadolinium chloride inhibits pulmonary macrophage influx and prevents O(2)-induced pulmonary hypertension in the neonatal rat. Pediatr Res 2001;50:172-83. https://doi.org/10.1203/00006450-200108000-00003
- Hoehn T, Stiller B, McPhaden AR, Wadsworth RM. Nitric oxide synthases in infants and children with pulmonary hypertension and congenital heart disease. Respir Res 2009;10:110. https://doi.org/10.1186/1465-9921-10-110
- Lee YH, Kim KC, Cho MS, Hong YM. Changes of pulmonary pathology and gene expressions after simvastatin treatment in the monocrotaline-induced pulmonary hypertension rat model. Korean Circ J 2011;41:518-27. https://doi.org/10.4070/kcj.2011.41.9.518
- Sutendra G, Dromparis P, Bonnet S, Haromy A, McMurtry MS, Bleackley RC, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension. J Mol Med (Berl) 2011;89:771-83. https://doi.org/10.1007/s00109-011-0762-2
Cited by
- Modafinil improves monocrotaline-induced pulmonary hypertension rat model vol.80, pp.1, 2013, https://doi.org/10.1038/pr.2016.38